Sparteine Metabolism Capacity in Human Liver: Structural Variants of Human P450IID6 as Assessed by Immunochemistry
- 1 July 1990
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 67 (1) , 14-18
- https://doi.org/10.1111/j.1600-0773.1990.tb00774.x
Abstract
An antibody raised against rat P450dbl was used to examine the heterogeneity of the human enzyme involved in the sparteine/debrisoquine polymorphism. The extent to which the antibody was able to inhibit sparteine metabolism varied in different human livers (10–80%, n = 9) and reflected the amount of sparteine metabolism carried out by the polymorphic P450IID6 in individual liver specimens. The individual sample variation in inhibition by the antibody correlated with the inhibition caused by quinidine, a prototype competitive inhibitor of the P450IID6 enzyme active site. Western immunoblots of the liver microsomes confirmed that the variation in the inhibition of sparteine metabolism by this antibody reflected the amount of P450IID6 protein. In addition, a detailed study of one of the livers (K 19) which demonstrated a lack of inhibition by the antibody was performed which confirmed the lack of P450IID6 in this liver specimen and suggested that the nascent sparteine metabolism activity was due to other forms of P450.This publication has 27 references indexed in Scilit:
- Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)Published by Elsevier ,2005
- The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA ratsBiochemistry, 1989
- Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in manBiochemistry, 1988
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- Debrisoquine 4-Hydroxylase: Characterization of a New P450 Gene Subfamily, Regulation, Chromosomal Mapping, and Molecular Analysis of the DA Rat PolymorphismDNA, 1987
- Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizersBiochemical and Biophysical Research Communications, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsLife Sciences, 1983
- Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in manLife Sciences, 1980
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977